Summary

Global Liver Cancer Diagnostics Market is valued approximately USD 9.6 billion in 2020 and is anticipated to grow with a healthy growth rate of more than 7.50 % over the forecast period 2021-2027. Liver cancer diagnostics is an advanced liver cancer diagnosis which is done by Chemotherapy and low-dose radiation may control the cancer's spread and ease pain. The rise in number of awareness program about early diagnosis of liver cancer is expected to rise the demand for liver cancer diagnostics market in the forecasted period. In 2018, the National Cancer Institute (NCI) funded a research program at Michigan Medicine for USD 33.4 million to alter the existing liver cancer surveillance and facilitate early detection of liver cancer in the U.S. Furthermore, increase in number of liver cancer patients is driving the growth for the market. According to the American Cancer Society, in 2021, around 42,230 new cases of liver cancer are diagnosed in the U.S., which will lead to around 30,230 deaths. Also, research and development programs and technological advancement is creating vast opportunity for the market. As, in June 2019, CancerSEEK a liquid biopsy test was designed by the researchers at Johns Hopkins University. The test was designed to diagnose multiple cancers including stomach, liver, ovarian, and esophageal among others an early stage, facilitating early treatment. However, high cost of technological advancement of liver cancer diagnostic solutions which might restrain the growth of the lover cancer diagnostics market in the forecasted period 2021-2027.

The key regions considered for the global Liver Cancer Diagnostics market study includes Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the significant region across the world in terms of market share owing to the well-established healthcare infrastructure, excellent healthcare insurance policies, and high adoption of innovative diagnostic tests. Whereas, Asia-Pacific is anticipated to exhibit highest growth rate over the forecast period 2021-2027. Factors such as high prevalence of hepatitis in emerging countries including India and China would create lucrative demand for liver cancer diagnostics market.
Major market player included in this report are:
Abbott Laboratories
F. Hoffmann-La Roche Ltd.
Qiagen N.V.
Thermo Fisher Scientific, Inc.
Siemens Healthineers
Becton Dickinson & Company
Illumina, Inc.
Koninklijke Philips N.V.
Epigenomics AG
Fujifilm Medical Systems U.S.A., Inc.

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:
By Test Type Outlook:
Laboratory Test
Imaging Tests
Endoscopy
Biopsy
Others
By End-Use Outlook:
Hospitals & Diagnostic Laboratories
Academic & Research Institutes
Pharmaceutical & CRO Laboratories
By Region:
North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Rest of the World

Furthermore, years considered for the study are as follows:

Historical year – 2018, 2019
Base year – 2020
Forecast period – 2021 to 2027

Target Audience of the Global Liver Cancer Diagnostics Market in Market Study:

Key Consulting Companies & Advisors
Large, medium-sized, and small enterprises
Venture capitalists
Value-Added Resellers (VARs)
Third-party knowledge providers
Investment bankers
Investors

ページTOPに戻る

Table of Contents

Chapter 1. Executive Summary
1.1. Market Snapshot
1.2. Global & Segmental Market Estimates & Forecasts, 2019-2027 (USD Billion)
1.2.1. Liver Cancer Diagnostics Market, by Region, 2019-2027 (USD Billion)
1.2.2. Liver Cancer Diagnostics Market, by Test Type Outlook, 2019-2027 (USD Billion)
1.2.3. Liver Cancer Diagnostics Market, by End-Use Outlook, 2019-2027 (USD Billion)
1.3. Key Trends
1.4. Estimation Methodology
1.5. Research Assumption
Chapter 2. Global Liver Cancer Diagnostics Market Definition and Scope
2.1. Objective of the Study
2.2. Market Definition & Scope
2.2.1. Scope of the Study
2.2.2. Industry Evolution
2.3. Years Considered for the Study
2.4. Currency Conversion Rates
Chapter 3. Global Liver Cancer Diagnostics Market Dynamics
3.1. Liver Cancer Diagnostics Market Impact Analysis (2019-2027)
3.1.1. Market Drivers
3.1.1.1. Rising awareness program of liver diagnosis
3.1.1.2. Increasing number of liver cancer patients
3.1.2. Market Challenges
3.1.2.1. High cost of technological advancement
3.1.3. Market Opportunities
3.1.3.1. Increasing research and development
Chapter 4. Global Liver Cancer Diagnostics Market Industry Analysis
4.1. Porter’s 5 Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s 5 Force Model (2018-2027)
4.2. PEST Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.3. Investment Adoption Model
4.4. Analyst Recommendation & Conclusion
4.5. Top investment opportunity
4.6. Top winning strategies
Chapter 5. Risk Assessment: COVID-19 Impact
5.1.1. Assessment of the overall impact of COVID-19 on the industry
5.1.2. Pre COVID-19 and post COVID-19 market scenario
Chapter 6. Global Liver Cancer Diagnostics Market, by Test Type Outlook
6.1. Market Snapshot
6.2. Global Liver Cancer Diagnostics Market by Test Type Outlook, Performance - Potential Analysis
6.3. Global Liver Cancer Diagnostics Market Estimates & Forecasts by Test Type Outlook 2018-2027 (USD Billion)
6.4. Liver Cancer Diagnostics Market, Sub Segment Analysis
6.4.1. Laboratory Test
6.4.2. Imaging Tests
6.4.3. Endoscopy
6.4.4. Biopsy
6.4.5. Others
Chapter 7. Global Liver Cancer Diagnostics Market, by End-Use Outlook
7.1. Market Snapshot
7.2. Global Liver Cancer Diagnostics Market by End-Use Outlook, Performance - Potential Analysis
7.3. Global Liver Cancer Diagnostics Market Estimates & Forecasts by End-Use Outlook 2018-2027 (USD Billion)
7.4. Liver Cancer Diagnostics Market, Sub Segment Analysis
7.4.1. Hospitals & Diagnostic Laboratories
7.4.2. Academic & Research Institutes
7.4.3. Pharmaceutical & CRO Laboratories
Chapter 8. Global Liver Cancer Diagnostics Market, Regional Analysis
8.1. Liver Cancer Diagnostics Market, Regional Market Snapshot
8.2. North America Liver Cancer Diagnostics Market
8.2.1. U.S. Liver Cancer Diagnostics Market
8.2.1.1. Test Type Outlook breakdown estimates & forecasts, 2018-2027
8.2.1.2. End-Use Outlook breakdown estimates & forecasts, 2018-2027
8.2.2. Canada Liver Cancer Diagnostics Market
8.3. Europe Liver Cancer Diagnostics Market Snapshot
8.3.1. U.K. Liver Cancer Diagnostics Market
8.3.2. Germany Liver Cancer Diagnostics Market
8.3.3. France Liver Cancer Diagnostics Market
8.3.4. Spain Liver Cancer Diagnostics Market
8.3.5. Italy Liver Cancer Diagnostics Market
8.3.6. Rest of Europe Liver Cancer Diagnostics Market
8.4. Asia-Pacific Liver Cancer Diagnostics Market Snapshot
8.4.1. China Liver Cancer Diagnostics Market
8.4.2. India Liver Cancer Diagnostics Market
8.4.3. Japan Liver Cancer Diagnostics Market
8.4.4. Australia Liver Cancer Diagnostics Market
8.4.5. South Korea Liver Cancer Diagnostics Market
8.4.6. Rest of Asia Pacific Liver Cancer Diagnostics Market
8.5. Latin America Liver Cancer Diagnostics Market Snapshot
8.5.1. Brazil Liver Cancer Diagnostics Market
8.5.2. Mexico Liver Cancer Diagnostics Market
8.6. Rest of The World Liver Cancer Diagnostics Market

Chapter 9. Competitive Intelligence
9.1. Top Market Strategies
9.2. Company Profiles
9.2.1. Abbott Laboratories
9.2.1.1. Key Information
9.2.1.2. Overview
9.2.1.3. Financial (Subject to Data Availability)
9.2.1.4. Product Summary
9.2.1.5. Recent Developments
9.2.2. F. Hoffmann-La Roche Ltd.
9.2.3. Qiagen N.V.
9.2.4. Thermo Fisher Scientific, Inc.
9.2.5. Siemens Healthineers
9.2.6. Becton Dickinson & Company
9.2.7. Illumina, Inc.
9.2.8. Koninklijke Philips N.V.
9.2.9. Epigenomics AG
9.2.10. Fujifilm Medical Systems U.S.A., Inc.
Chapter 10. Research Process
10.1. Research Process
10.1.1. Data Mining
10.1.2. Analysis
10.1.3. Market Estimation
10.1.4. Validation
10.1.5. Publishing
10.2. Research Attributes
10.3. Research Assumption